"Pharmaceutical leader" is the world's first car-t therapy approved for health insurance TPA investment in China
-
Last Update: 2019-10-31
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
(2019 / 10 / 31) in 2019, it is estimated that the sales volume of Jingfeng pharmaceutical auxiliary drugs will decline seriously with a loss of 200-300 million yuan; Yuyue Medical Co., Ltd will purchase 66 vision rich ophthalmic categories with a cost of 37.42 million yuan; the development status of gene therapy vector industry in China in 2019; Gardasil, the MSD HPV vaccine, will meet the global demand by 2023 Wait a minute! It's a new tuyere There are more and more overrated varieties New king is born! Acquisitions don't stop First in the world! It's everyone's responsibility to eradicate the black and evil! The only difference is everywhere The end of adjuvant medicine has come.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
